Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in

Jared R Thomas1, Kourtney Sloan1, Kelsey Cave1

  • 1Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN 46202, USA.

Genes
|November 27, 2021
PubMed

Insights

Down syndrome (DS) causes skeletal abnormalities, with males affected earlier than females. Reducing DYRK1A gene copies in osteoblasts did not improve bone structure in DS mouse models, indicating other factors are involved.

Area of Science:

  • Genetics and Developmental Biology
  • Skeletal Biology
  • Down Syndrome Research

Background:

  • Trisomy 21 (Ts21) leads to skeletal deficits in Down syndrome (DS), including reduced bone mass and altered bone structure.
  • A sexual dimorphism exists in DS skeletal abnormalities, with males experiencing earlier bone density deficits than females.
  • The gene DYRK1A, present in three copies in DS, is implicated in postnatal skeletal phenotypes.

Purpose of the Study:

  • To investigate the role of DYRK1A gene dosage in osteoblasts on skeletal development in DS mouse models.
  • To determine if reducing DYRK1A copy number in osteoblasts can rescue skeletal structural anomalies in trisomic mice.

Main Methods:

  • Generation of trisomic Ts65Dn mice with reduced DYRK1A copy number specifically in osteoblasts using a floxed DYRK1A gene and Osx-Cre system.
  • Analysis of trabecular architecture and cortical geometry in P42 male and female trisomic and euploid mice.
  • Comparison of skeletal phenotypes across different DS mouse models (Ts65Dn, Dp1Tyb) to assess strain and sex-dependent effects.

Main Results:

  • Reducing DYRK1A copy number in osteoblasts of Ts65Dn mice did not improve trabecular architecture or cortical geometry at P42.
  • Trisomic DYRK1A does not appear to autonomously affect osteoblast function at or before P42.
  • Skeletal deficits in DS mouse models are sex, age, and strain-dependent, and not solely caused by DYRK1A overexpression in osteoblasts.

Conclusions:

  • Overexpression of DYRK1A in osteoblasts is not the sole driver of skeletal deficits in DS mouse models.
  • Further research is needed to identify other molecular and cellular mechanisms underlying DS-associated skeletal abnormalities.
  • Understanding these mechanisms is crucial for developing targeted therapies for skeletal deficiencies in Down syndrome.